Actionable news
All posts from Actionable news
Actionable news in NVO: NOVO-NORDISK A/S,

Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp(R) (fast-acting insulin aspart) for the treatment of diabetes

(GLOBE NEWSWIRE via COMTEX) -- Bagsvaerd, Denmark, 11 November 2016 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of Fiasp(R) (fast-acting insulin aspart), recommending marketing authorisation for the treatment of adults with type 1 and type 2 diabetes.

The CHMP recommends Fiasp(R), the intended brand name for fast-acting insulin aspart, to be indicated for use as the bolus component of basal-bolus therapy in combination with basal insulin and for continuous subcutaneous insulin infusion via an insulin pump. Novo Nordisk has developed Fiasp(R) as mealtime insulin with an earlier and greater glucose-lowering effect than NovoRapid(R) (insulin aspart).